![]() |
市场调查报告书
商品编码
1401917
2030 年精准医疗市场预测:按产品类型、药物类型、给药途径、定序技术、技术、应用、最终用户和地区进行的全球分析Precision Medicine Market Forecasts to 2030 - Global Analysis By Product Type, By Drug Type, Route of Administration, Sequencing Technology, Technology, Application, End User and By Geography |
根据Stratistics MRC预测,2023年全球精准医疗市场规模将达834亿美元,预计2030年将达到2023亿美元,预测期内复合年增长率为13.5%。
精准医疗考虑基因、环境和生活方式的个体差异,客製化医疗保健,帮助预防和治疗疾病。它依靠基因组定序和资料分析等先进技术,根据个人的独特特征来制定医疗决策和治疗方法。这种方法旨在透过强调个体化和有针对性的干预措施来优化疗效、最大限度地减少副作用并改善整体健康结果。
据世界卫生组织称,到本十年末,癌症发病率预计将上升 50%,癌症发病率将超过 2,000 万人。
扩大新基因组技术的使用
新兴的基因组技术越来越多地用于透过提供对个体基因组成前所未有的洞察来推进精准医学。次世代定序、基于 CRISPR 的基因编辑和先进的生物资讯学能够实现全面分析和识别与疾病相关的遗传变异。这些丰富的基因组资料有助于准确的诊断、预后和个体化治疗策略,以优化治疗结果。此外,这些技术的可近性和可负担性的提高将进一步使基因组资讯民主化,并使精准医学得到更广泛的应用。
与治疗相关的费用增加
客製化治疗通常依赖先进技术和专门药物,费用可能高得令人望而却步。这种经济负担影响了可近性并限制了这些个体化治疗的普及。此外,报销挑战和覆盖范围差异进一步阻碍了患者获得服务。
对细胞和基因治疗的需求不断增加
对细胞和基因治疗日益增长的需求代表着精准医学的重大机会。这些疗法通常根据个人的基因特征量身定制,是精准医疗个人化方法的个体化代表。生物技术的进步使得能够开发出在基因层面上解决各种疾病的创新治疗方法。随着精准医学的进步,对客製化细胞和基因疗法的需求将会增加,为研究、开发和市场扩张铺平道路。
严格的监管标准
严格的法规可能会延长核准流程并阻碍及时获得创新疗法。合规性需要严格的有效性证据,这会增加研发成本,并可能阻止小型企业和新兴企业进入市场。此外,多样化的全球监管环境使区域标准化和核准变得复杂,阻碍了精准治疗的无缝实施。
COVID-19大流行加速了技术和调查方法的进步,对精准医疗市场产生了重大影响。这次大流行凸显了对个体化医疗解决方案的迫切需求,并强调了快速诊断、疫苗开发和治疗方法的重要性。此外,它还促进了全球科学界之间的合作,促进了技术创新,并促进了精准医学原理与感染疾病管理的结合。
预计在预测期内,口服细分市场将是最大的
口腔领域预计将主导精准医疗市场,因为它提供方便且患者友善的标靶治疗。这种给药方法提高了患者的依从性,并允许根据个人的遗传特征制定个体化的治疗计划。口服给药的普及将促进精准医疗的广泛采用并将其融入日常医疗保健中。此外,口服药物配方和技术的进步为医疗保健专业人员提供了提供准确有效治疗的选择,从而有助于保持该细分市场的领先地位。
药物研发领域预计在预测期内复合年增长率最高
由于人工智慧、基因组学和高通量筛检等技术进步,预计药物研发领域将在精准医学市场显着成长。这些进步将加速标靶识别、检验和药物开发,并简化客製化治疗的创建。精准医学对个体差异的关注需要强大的药物管道,从而推动该领域的投资和创新。此外,生物技术、製药公司和研究机构之间的合作正在培育新的方法,从而能够发现高度特异性的治疗方法,并且该领域预计将持续扩展。
北美地区占据了最大占有率,并有望主导市场。该地区拥有先进的医疗基础设施、强大的研发措施以及慢性病的高盛行率。有利的政府政策、对精准医疗的大量投资以及主要行业参与者的强大影响力奠定了北美的领导地位。此外,完善的法律规范和积极采用创新医疗技术的方法进一步增强了该地区的优势。
由于医疗保健基础设施的快速进步和基因组学投资的增加,预计亚太地区精准医疗市场将快速成长。此外,具有不同遗传背景的快速增长的人口需要量身定制的医疗保健解决方案。此外,意识的提高和支持性法律规范正在推动精准医疗的采用。总而言之,这些动态使该地区成为成长最快的精准医疗市场。
According to Stratistics MRC, the Global Precision Medicine Market is accounted for $83.4 billion in 2023 and is expected to reach $202.3 billion by 2030 growing at a CAGR of 13.5% during the forecast period. Precision Medicine customizes healthcare by considering individual variability in genes, environment and lifestyle for disease prevention and treatment. It relies on advanced technologies, like genomic sequencing and data analytics, to tailor medical decisions and therapies to a person's unique characteristics. This approach aims to optimize effectiveness, minimize side effects, and improve overall health outcomes by emphasizing personalized, targeted interventions.
According to WHO, cancer incidence is projected to rise by 50% to reach more than 20 million by the end of this decade.
Growing utilization of emerging genomic technologies
The escalating use of emerging genomic technologies propels precision medicine by providing unprecedented insights into an individual's genetic makeup. Next-generation sequencing, CRISPR-based gene editing, and advanced bioinformatics enable comprehensive analysis, identifying genetic variations linked to diseases. This wealth of genomic data facilitates precise diagnosis, prognosis, and personalized treatment strategies, optimizing therapeutic outcomes. Additionally, the growing accessibility and affordability of these technologies further democratize genomic information, making precision medicine more widely applicable.
Elevated expenses associated with therapeutic
Tailored treatments, often relying on advanced technologies and specialized medications, can be prohibitively expensive. This financial burden affects accessibility, limiting widespread adoption of these personalized therapies. Additionally, reimbursement challenges and insurance coverage gaps further hinder patient access.
Increasing need for cell and gene therapies
The escalating demand for cell and gene therapies presents a significant opportunity in precision medicine. These therapies, often tailored to individual genetic profiles, exemplify the personalized approach of precision medicine. Advances in biotechnology allow for the development of innovative treatments addressing various diseases at the genetic level. As precision medicine evolves, the growing need for customized cell and gene therapies opens avenues for research, development, and market expansion.
Strict regulatory standards
Stringent regulations may lengthen the approval process, impeding timely access to innovative treatments. Compliance demands rigorous evidence of efficacy, increasing research and development costs, which could deter smaller firms or startups from entering the market. Additionally, diverse global regulatory landscapes create complexities in standardization and approval across regions, hindering the seamless adoption of precision therapies.
The COVID-19 pandemic significantly influenced the precision medicine market by accelerating advancements in technology and research methodologies. It highlighted the critical need for personalized healthcare solutions and underscored the importance of rapid diagnostics, vaccine development, and treatment modalities. Additionally, it spurred collaborations among global scientific communities, fostering innovation and expediting the integration of precision medicine principles into infectious disease management.
The oral segment is expected to be the largest during the forecast period
The oral segment is anticipated to dominate the precision medicine market as it offers convenient and patient-friendly administration of targeted therapies. This mode of delivery enhances patient compliance and allows for personalized treatment plans tailored to individual genetic profiles. The ease of oral medication fosters widespread adoption, facilitating the integration of precision medicine into routine healthcare practices. Additionally, advancements in oral drug formulations and technologies contribute to the segment's leadership, providing healthcare professionals with more options for delivering precise and effective treatments.
The drug discovery segment is expected to have the highest CAGR during the forecast period
The drug discovery segment is estimated to register remarkable growth within the precision medicine market owing to technological strides like AI, genomics, and high-throughput screening. These advancements expedite target identification, validation, and drug development, streamlining the creation of tailored therapies. Precision medicine's focus on individual variations demands a robust pipeline of drugs, propelling investment and innovation in this sector. Additionally, collaborations between biotech, pharmaceutical companies and research institutions foster novel approaches enabling the discovery of highly specific treatments, which positions this segment for sustained expansion.
North America is poised to dominate the market, securing the largest share. The region boasts advanced healthcare infrastructure, robust research and development initiatives, and a high prevalence of chronic diseases. Favorable government policies, substantial investments in precision medicine, and a strong presence of key industry players contribute to North America's leadership. Additionally, a well-established regulatory framework and a proactive approach to adopting innovative medical technologies further bolster the region's dominance.
The Asia Pacific region is anticipated to witness exponential growth in the precision medicine market owing to rapid advancements in healthcare infrastructure and expanding investments in genomics. Moreover, a burgeoning population with diverse genetic backgrounds necessitates tailored healthcare solutions. Additionally, growing awareness, coupled with supportive regulatory frameworks, propels the adoption of precision medicine. Altogether, these dynamics fuel the region to experience the highest surge in precision medicine market expansion.
Some of the key players in Precision Medicine Market include Astarte Medical, AstraZeneca PLC, Biocrates Life Sciences, Biogen, Bristol-Myers Squibb, Eagle Genomics, Labcorp, Medtronic PLC, Menarini Silicon Biosystems, Myriad Genetics Inc., NanoString Technologies, Novartis AG, Pfizer Inc., Qiagen NV, Quest Diagnostics, Roche, Tepnel Pharma Services, Teva Pharmaceutical and Thermo Fisher Scientific Inc.
In November 2023, Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. and Royalty Pharma plc, announced a collaboration to further accelerate the clinical research program for Teva's olanzapine LAI (TEV-'749) by entering into a funding agreement of up to $125 million to offset program costs. Olanzapine LAI (TEV-'749) is a once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine that is currently in Phase 3 for the treatment of schizophrenia and has the potential to be the first long-acting olanzapine with a favorable safety profile.
In October 2023, Medtronic plc, a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for the Aurora EV-ICD™ MRI SureScan™ (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV™ MRI SureScan™ defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest (SCA). The Aurora EV-ICD system is the first-of-its-kind to provide the life-saving benefits of traditional, transvenous ICDs with a lead (thin wire) placed under the breastbone, outside of the heart and veins. The Aurora EV-ICD delivers lifesaving defibrillation, anti-tachycardia pacing (ATP), and back-up (pause-prevention) pacing therapies via a device similar in size, shape, and longevity to traditional, transvenous ICDs.
In October 2023, Labcorp, a global leader of innovative and comprehensive laboratory services, announced it will acquire Baystate Health, Inc.'s (Baystate Health) outreach laboratory business and select operating assets, including laboratory service centers operated by Baystate Health throughout Massachusetts. This strategic relationship will build upon Labcorp's and Baystate Health's existing reference laboratory relationship to improve the efficiency of routine and specialty lab testing.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.